Figure 1 (Pravastatin Fig1)
This text provides information on the survival distributions of subjects without event, specifically Coronary Heart Disease Death or Nonfatal Myocardial Infarction. It includes the proportions of subjects without event for the placebo and pravastatin groups over the years since randomization. The logrank test p-value is also mentioned as 0.0001, indicating a statistically significant difference between the two groups.*